# Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

> **NCT02657928** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 40 (actual)

## Conditions studied

- Estrogen Receptor Positive
- Postmenopausal
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Uterine Corpus Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Letrozole
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT02657928
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-08
- **Primary completion:** 2018-05-21
- **Final completion:** 2020-10-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02657928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02657928, "Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02657928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*